Early exposure to broadly neutralizing antibodies may trigger a dynamical switch from progressive disease to lasting control of SHIV infection
Fig 6
Early bNAb therapy induces a switch to viremic control.
(a,b) Model fits (blue lines) to viral load data [10] (symbols) from the responder macaques DEWP and MVJ, representative of macaques displaying minimal or substantial viral load rebound post therapy, respectively. (The parameter values used are in Table 1 and S1 Table). The corresponding dynamics of (c,d) the effector response and (e,f) the level of effector exhaustion. The phases are color coded as in Fig 2. Red lines in all panels indicate model predictions with the same parameter values but in the absence of bNAb therapy. Our model predicts thus that bNAb therapy switches disease dynamics from reaching the high viremic, disease progressive state to the state of viremic control. Black dotted lines in (a,b) indicate the viral load detection limit (100 RNA copies/mL).